| Identification | Back Directory | [Name]
E3 Ligase Ligand-Linker Conjugates 19 | [CAS]
1799711-24-2 | [Synonyms]
Thalidomide-O-amido-C4-NH2
E3 Ligand-Linker Conjugate 3
Cereblon Ligand-Linker Conjugates 6
E3 Ligase Ligand-Linker Conjugates 19
N-(4-aminobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
Acetamide, N-(4-aminobutyl)-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- | [Molecular Formula]
C19H22N4O6 | [MDL Number]
MFCD31630818 | [MOL File]
1799711-24-2.mol | [Molecular Weight]
402.4 |
| Chemical Properties | Back Directory | [Boiling point ]
757.5±60.0 °C(Predicted) | [density ]
1.397±0.06 g/cm3(Predicted) | [solubility ]
DMF: insol; DMSO: insol; Ethanol: insol; PBS (pH 7.2): 3 mg/ml | [form ]
A solid | [pka]
10.68±0.40(Predicted) |
| Hazard Information | Back Directory | [Description]
Thalidomide-O-acetamido-C4-amine HCl salt is comprised of a Thalidomide based cereblon ligand and a ligand-linker conjugate. This E3 ligase ligand-linker conjugate is used in PROTAC technology. | [Uses]
Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs[1]. | [IC 50]
Cereblon | [References]
[1] Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins withPicomolar Cellular Potencies and Capable of Achieving Tumor Regression.J Med Chem. 2018 Jan 25;61(2):462-481. DOI:10.1021/acs.jmedchem.6b01816
[2] James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2. |
|
|